# RT-310 Safety and Feasibility BPH Study

> **NCT07264205** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Resurge Therapeutics Inc.** · enrollment: 20 (estimated)

## Conditions studied

- BPH (Benign Prostatic Hyperplasia)

## Interventions

- **COMBINATION_PRODUCT:** RT-310

## Key facts

- **NCT ID:** NCT07264205
- **Lead sponsor:** Resurge Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-13
- **Primary completion:** 2026-03
- **Final completion:** 2026-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264205, "RT-310 Safety and Feasibility BPH Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07264205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*